Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 246-356-2 | CAS number: 24613-89-6
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
The acute oral LD50 of dichromium tris(chromate), tested as a water dilution (25% corresponding to 23.6% active ingredient) was between 50 and 300 mg active ingredient/kg bw in female rats in a recent GLP guideline study. The acute dermal LD50 of dichromium tris(chromate) 25% solution was found to be greater than 2000 mg active ingredient/kg bw in rats, in a recent GLP guideline study. No data are available for inhalation toxicity; the EU RAR (2005) reviews the data regarding the inhalation toxicity of other Cr (VI) compounds, reported LC50 values range from 99 to 217 mg/m³.
Key value for chemical safety assessment
Additional information
Acute toxicity: oral
The acute oral toxicity of dichromium tris(chromate) 25% solution was evaluated in female rats, in a GLP study according to the acute toxic class method OECD 423 (Tavaszi, 2010). The test substance was administered as a single oral dose by gavage, rats were observed for 14 days post-administration and necropsies were performed on all animals. The first group of 3 females were dosed with 300 mg active ingredient/kg bw. All 3 rats died within 6 hours of dosing, therefore the second group was dosed with 50 mg active ingredient/kg bw. No deaths occurred, so a confirmatory group was also dosed with 50 mg/kg bw. Clinical signs observed in all 3 rats administered 300 mg/kg were decreased activity, hunched posture, dyspnoea, piloerection, soft faeces and death. No mortalities occurred in the animals administered 50 mg/kg, and no clinical signs were observed in these animals.
Necropsy of the animals dosed with 300 mg/kg revealed dark/brown discolouration of the oesophagus, stomach and/or digestive content, as well as dark/brown discolouration of the lungs associated with yellow liquid in the trachea or nasal cavity. There were no abnormal findings in the 50 mg/kg animals.
The acute oral LD50 of dichromium tris(chromate) 25% solution was found to be between 50 and 300 mg active ingredient/kg bw in female rats.
Acute toxicity: inhalation
No data are available for dichromium tris(chromate). Further testing is not required due to the corrosive nature of Cr (VI) compounds, and on the basis that acute toxicity data for the oral and dermal exposure routes are available. Information regarding the inhalation toxicity of a number of other Cr (VI) compounds is available in the EU RAR (2005), and is presented here in a weight of evidence approach in support of proposed changes to the classification of dichromium tris(chromate):
The EU RAR (2005) reviews the available data for a number of Cr (VI) compounds, which indicates that this group of chemicals are toxic by inhalation. The EU RAR states that potassium dichromate aerosols (mass median aerodynamic diameter 1-2 microns) were toxic when inhaled by rats, deaths occurring following a 6-hour exposure to 37 mg/m³ (13 mg Cr (VI)/m³) and above. There were no deaths at 31 mg/m³ (11 mg Cr(VI)/m³). Decreased body weight gain and increased lung weight were observed following 2 -hour exposure to 20 mg/m³ (7 mg Cr(VI)/m³). LC50 values of 99 mg/m³ (potassium dichromate) (35 mg Cr(VI)/m³), 200 mg/m³ (sodium and potassium dichromate) (70 mg Cr(VI)/m³) and 104 mg/m³ (sodium chromate) (33 mg Cr(VI)/m³) have been reported for male rats with a 4-hour aerosol exposure period. Signs of toxicity included reduced body weight, respiratory distress and irritation of the respiratory tract. Lung oedema, inflammation and tracheal epithelium necrosis were seen in rats following inhalation of 28 mg/m³ sodium chromate (9 mg Cr(VI)/m³) for 24 hours; minimal lung effects (reduction in glycoprotein secretion in the trachea) were seen at 8 mg/m³ (3 mg Cr(VI)/m³) for 24 hours. Intratracheal instillation of potassium dichromate at 1.14 mg (0.4 mg Cr(VI)) produced lung inflammation in rats. An LC50 value of 217 mg/m³ (113 mg Cr(VI)/m³) for chromium (VI) trioxide (presumably aerosol) has been reported for rats with a 4-hour exposure period. It is predicted that severe damage to tissues of the respiratory tract would occur at low concentrations due to the corrosive nature of this substance. In the case of all the Cr (VI) compounds under consideration, depending upon the pH of the Cr (VI) solution, corrosive effects can occur on contact.
Acute toxicity: dermal
The acute dermal toxicity of dichromium tris(chromate), tested as a water dilution (25% corresponding to 23.6% active ingredient) was evaluated in male and female rats, according to OECD 402 (Zelenak, 2010). The test material was applied to the shaved intact dorsal skin at doses of 175, 350, 850, 1400 and 2000 mg active ingredient/kg bw, and held in place using a semi-occlusive dressing for 24 hours. The rats were observed for 14 days following removal of the dressings, and were necropsied at the end of the observation period. There were no mortalities, no clinical signs were observed, and no abnormalities were detected at necropsy. Discolouration of the hair and skin at the test site was noted. It was concluded that the acute dermal LD50 of dichromium tris(chromate) 25% solution is >2000 mg active ingredient/kg bw in rats.
Justification for classification or non-classification
The acute oral LD50 of dichromium tris(chromate) was between 50 and 300 mg active ingredient/kg bw in female rats. Based on the results of the acute oral study, dichromium tris(chromate) should be classified as Toxicity Category 3 according to UN GHS and Regulation (EC) No 1272/2008. The acute dermal LD50 of dichromium tris(chromate) 25% solution was greater than 2000 mg active ingredient/kg bw in rats. The substance is not classified as acutely toxic by the dermal route according to UN GHS and Regulation (EC) No 1272/2008 criteria, and no changes to this classification are proposed. Based on information available regarding other soluble Cr (VI) compounds, dichromium tris(chromate) should be classified as toxic by inhalation Toxicity Category 2 according to UN GHS and Regulation (EC) No 1272/2008.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.